Dorsey Wright & Associates Takes Position in Grifols, S.A. $GRFS

Dorsey Wright & Associates acquired a new position in Grifols, S.A. (NASDAQ:GRFS) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 145,236 shares of the biotechnology company’s stock, valued at approximately $1,447,000.

A number of other institutional investors also recently bought and sold shares of GRFS. Versant Capital Management Inc grew its holdings in Grifols by 39.5% during the third quarter. Versant Capital Management Inc now owns 5,598 shares of the biotechnology company’s stock valued at $56,000 after purchasing an additional 1,584 shares during the period. Peterson Wealth Services raised its stake in shares of Grifols by 385.8% in the third quarter. Peterson Wealth Services now owns 7,287 shares of the biotechnology company’s stock worth $73,000 after buying an additional 5,787 shares during the period. EverSource Wealth Advisors LLC raised its stake in shares of Grifols by 127.4% in the second quarter. EverSource Wealth Advisors LLC now owns 8,219 shares of the biotechnology company’s stock worth $74,000 after buying an additional 4,604 shares during the period. PNC Financial Services Group Inc. lifted its position in shares of Grifols by 109.8% during the 3rd quarter. PNC Financial Services Group Inc. now owns 8,634 shares of the biotechnology company’s stock valued at $86,000 after buying an additional 4,518 shares in the last quarter. Finally, Ameriprise Financial Inc. bought a new position in shares of Grifols during the 2nd quarter valued at approximately $95,000.

Grifols Stock Performance

Shares of GRFS opened at $8.02 on Wednesday. The business’s 50 day moving average is $9.02 and its 200 day moving average is $9.19. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.51 and a quick ratio of 0.88. Grifols, S.A. has a 12-month low of $6.19 and a 12-month high of $11.14.

Analyst Ratings Changes

Several research firms recently issued reports on GRFS. Zacks Research raised shares of Grifols from a “strong sell” rating to a “hold” rating in a report on Friday, February 6th. Wall Street Zen lowered shares of Grifols from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. JPMorgan Chase & Co. reduced their price objective on shares of Grifols from $10.30 to $10.00 and set a “neutral” rating for the company in a research note on Monday, December 8th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Grifols in a research report on Thursday, January 22nd. Four research analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, Grifols currently has an average rating of “Hold” and an average target price of $10.00.

Grifols Profile

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.